SI
BMRN icon

Sava Infond’s BioMarin Pharmaceuticals BMRN Stock Holding History

Sava Infond’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$186K Hold
3,250
– – 0.01% 190
2026
Q1 		$184K Hold
3,250
– – 0.03% 187
2025
Q4 		$193K Hold
3,250
– – 0.03% 173
2025
Q3 		$176K Hold
3,250
– – 0.03% 176
2025
Q2 		$179K Hold
3,250
– – 0.03% 176
2025
Q1 		$230K Hold
3,250
– – 0.04% 162
2024
Q4 		$214K Buy
+3,250
New +$218K 0.04% 169

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Sava Infond's BMRN Position: Q2 2026 in Review

Sava Infond held its BioMarin Pharmaceuticals (BMRN) position steady in Q2 2026 at 3,250 shares worth $186K. The position accounts for 0.01% of the portfolio, ranked #190.

Sava Infond first reported a position in BMRN in Q4 2024 and has held it in 7 quarters since. The position peaked at $230K in Q1 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Sava Infond held 3,250 shares of BioMarin Pharmaceuticals worth $186K as of Q2 2026.
  • Sava Infond left its BioMarin Pharmaceuticals share count unchanged in Q2 2026.
  • BioMarin Pharmaceuticals made up 0.01% of Sava Infond's portfolio in Q2 2026, its #190 holding.
  • Sava Infond first reported a position in BioMarin Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • Sava Infond's BioMarin Pharmaceuticals position peaked at $230K in Q1 2025.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Sava Infond's 13F filing for Q2 2026, filed 16 Jul 2026.